Merck Receives Priority Review From FDA for New Drug Application for HIF-2 α Inhibitor Belzutifan (MK-6482)

KENILWORTH, N.J.--(BUSINESS WIRE) March 16, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news